2024-04-12 08:45:00
After the initial rejection of Respiratorius' patent application, the US Patent and Trademark Office's Patent Trial and Appeal Board has now sided with the company. The decision means a reopening of the application regarding the oral formulation of VAL001. BioStock has contacted CEO Johan Drott to gain a better understanding of what this implies for the project.
Read the full article at biostock.se (https://www.biostock.se/en/):
https://www.biostock.se/en/2024/04/respiratorius-us-patent-application-reopens/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se